AUTL
Autolus Therapeutics PLC
Position levels
Currenttoday
USD 1.49
Buy <=wait / entry
USD 1.22
Trim >=take some off
USD 1.75
Thesis breakA guidance reset below the lower bound of the 2026 AUCATZYL range combined with ...
-
Scenario-weighted conviction
| Probability | Score | Contribution | |
|---|---|---|---|
| Bull case | 21% | 100 / 100 | 21.0 |
| Base case | 50% | 62 / 100 | 31.0 |
| Bear case | 29% | 10 / 100 | 2.9 |
| Weighted conviction | 55 / 100 - OPPORTUNISTIC BUY | ||
Top risks
- Strategic collaboration with BioNTech including $200M investment, manufacturing access, and co-commercialization options for obe-cel and other programs
- Reiterated 2026 AUCATZYL net revenue guidance of $120 - $135 million with expected positive gross margin
- Operational efficiency initiative including doubled manufacturing capacity and ~$15M annualized operating expense reduction beginning 2027